Search The Medical Knowledge Base

Drug Details

Vagifem 25 micrograms film-coated tablets

• Drug Class Description
  Natural and semisynthetic oestrogens - ATC code G03C A03
• Generic Name
  estradiol hemihydrate
• Presentation
  Film-coated vaginal tablet inset in disposable applicator.
• Description
  One vaginal tablet contains: Estradiol hemihydrate equivalent to estradiol 25 micrograms.
• Indications
  

  Hormone replacement therapy for the treatment of vaginal atrophy due to oestrogen deficiency.

  The experience of treating women older than 65 years is limited.

• Adult Dosage
  

  Dosage

  Vagifem^® is administered intravaginally using the applicator. An initial dose of one tablet daily for two weeks will usually improve vaginal atrophy and associated symptoms; a maintenance dose of two tablets per week should then be instituted.

  Treatment may be started on any convenient day.

  If a dose is forgotten, it should be administered as soon as the patient remembers. A double dose should be avoided.

  For initiation and continuation of treatment of postmenopausal symptoms, the lowest effective dose for the shortest duration should be used.

  Vagifem^® may be used in women with or without an intact uterus.

  The addition of a progestogen is not recommended during treatment with Vagifem^®

  Administration

  The applicator is inserted into the vagina up to the end of the smooth part of the applicator (approximately 9 cms). The tablet is released by pressing the plunger. The applicator is then withdrawn and disposed of.

• Child Dosage
  

  Not intended for children or males.

• Elderly Dosage
  

  There are no special dosage requirements.

• Contra Indications
  

  Known, past or suspected breast cancer.

  Known, past or suspected oestrogen-dependent malignant tumours (eg endometrial cancer).

  Undiagnosed genital bleeding.

  Untreated endometrial hyperplasia.

  Previous idiopathic or current venous thromboembolism (deep venous thrombosis, pulmonary embolism).

  Active or recent arterial thromboembolic disease (e.g. angina, myocardial infarction.

  Acute liver disease or history of liver disease as long as liver function tests have failed to return to normal.

  Known hypersensitivity to the active substance or to any of the excipients.

  Porphyria.

• Special Precautions
  

  For the treatment of postmenopausal symptoms, HRT should only be initiated for symptoms that adversely affect quality of life. In all cases, a careful appraisal of the risks and benefits should be undertaken annually and HRT should only be continued as long as the benefit outweighs the risk.

  Medical examination/follow-up

  Before initiating or reinstituting HRT, a complete personal and family medical history should be taken. Physical (including pelvic and breast) examination should be guided by this and by the contra-indications and warnings for use. During treatment, periodic check-ups are recommended of a frequency and nature adapted to the individual woman. Women should be advised what changes in their breasts should be reported to their doctor or nurse. Investigations, including mammography, should be carried out in accordance with currently accepted screening practices, modified to the clinical needs of the individual.

  Vaginal infections should be treated before initiation of Vagifem^® therapy.

  Due to the intermittent administration of low dose estradiol in Vagifem^®, low systemic exposure of estradiol is expected, however being an HRT product the following need to be considered especially for long-term or repeated use of this product.

  Conditions which need supervision

  If any of the following conditions are present, have occurred previously, and/or have been aggravated during pregnancy or previous hormone treatment, the patient should be closely supervised. It should be taken into account that these conditions may recur or be aggravated during systemic oestrogen treatment, in particular:

  - Leiomyoma (uterine fibroids) or endometriosis

  - A history of, or risk factors for, thromboembolic disorders (see below)

  - Risk factors for oestrogen dependent tumours, e.g. 1st degree heredity for breast cancer

  - Hypertension

  - Liver disorders (e.g. liver adenoma)

  - Diabetes mellitus with or without vascular involvement

  - Cholelithiasis

  - Migraine or (severe) headache

  - Systemic lupus erythematosus

  - A history of endometrial hyperplasia (see below)

  - Epilepsy

  - Asthma

  - Otosclerosis

  Reasons for immediate withdrawal of therapy

  Therapy should be discontinued in case a contra-indication is discovered and in the following situations:

  - Jaundice or deterioration in liver function

  - Significant increase in blood pressure

  - New onset of migraine-type headache

  - Pregnancy

  Endometrial hyperplasia

  The risk of endometrial hyperplasia and carcinoma is increased when systemic oestrogens are administered for prolonged periods of time. The endometrial safety of long-term or repeated use of topical vaginal oestrogens is uncertain. Therefore, if repeated, treatment should be reviewed at least annually, with special consideration given to any symptoms of endometrial hyperplasia or carcinoma.

  If bleeding or spotting appears at any time on therapy, the reason should be investigated, which may include endometrial biopsy to exclude endometrial malignancy.

  Unopposed oestrogen stimulation may lead to premalignant or malignant transformation in the residual foci of endometriosis. Therefore caution is advised when using this product in women who have undergone hysterectomy because of endometriosis, especially if they are known to have residual endometriosis.

  Vagifem^® is a local low dose preparation and therefore the occurrence of the below mentioned conditions is less likely than that with systemic oestrogen treatment.

  Breast cancer

  A randomised placebo-controlled trial, the Women's Health Initiative study (WHI), and epidemiological studies, including the Million Women Study (MWS), have reported an increased risk of breast cancer in women taking estrogens, estrogen-progestagen combinations or tibolone for HRT for several years. For all HRT, an excess risk becomes apparent within a few years of use and increases with duration of intake but returns to baseline within a few (at most five) years after stopping treatment.

  In the MWS, the relative risk of breast cancer with conjugated equine estrogens (CEE) or estradiol (E2) was greater when a progestagen was added, either sequentially or continuously, and regardless of type of progestagen. There was no evidence of a difference in risk between the different routes of administration.

  In the WHI study, the continuous combined conjugated equine estrogen and medroxyprogesterone acetate (CEE + MPA) product used was associated with breast cancers that were slightly larger in size and more frequently had local lymph node metastases compared to placebo. HRT, especially estrogen-progestagen combined treatment, increases the density of mammographic images which may adversely affect the radiological detection of breast cancer.

  Venous thromboembolism

  Systemic HRT is associated with a higher relative risk of developing venous thromboembolism (VTE), i.e. deep vein thrombosis or pulmonary embolism. One randomised controlled trial and epidemiological studies found a two- to threefold higher risk for users compared with non-users. For non-users it is estimated that the number of cases of VTE that will occur over a 5 year period is about 3 per 1000 women aged 50-59 years and 8 per 1000 women aged between 60-69 years. It is estimated that in healthy women who use HRT for 5 years, the number of additional cases of VTE over a 5 year period will be between 2 and 6 (best estimate = 4) per 1000 women aged 50-59 years and between 5 and 15 (best estimate = 9) per 1000 women aged 60-69 years. The occurrence of such an event is more likely in the first year of HRT than later.

  Generally recognised risk factors for VTE include a personal history or family history, severe obesity (BMI >30 kg/m²) and systemic lupus erythematosus (SLE). There is no consensus about the possible role of varicose veins in VTE.

  Patients with a history of VTE or known thrombophilic states have an increased risk of VTE. HRT may add to this risk. Personal or strong family history of thromboembolism, or recurrent spontaneous abortion, should be investigated in order to exclude a thrombophilic predisposition. Until a thorough evaluation of thrombophilic factors has been made or anticoagulant treatment initiated, use of HRT in such patients should be viewed as contraindicated. Those women already on anticoagulant treatment require careful consideration of the benefit-risk of use of HRT.

  The risk of VTE may be temporarily increased with prolonged immobilisation, major trauma or major surgery. As in all postoperative patients, scrupulous attention should be given to prophylactic measures to prevent VTE following surgery. Where prolonged immobilisation is liable to follow elective surgery, particularly abdominal or orthopaedic surgery to the lower limbs, consideration should be given to temporarily stopping HRT 4 to 6 weeks earlier, if possible. Treatment should not be restarted until the woman is completely mobilised.

  If VTE develops after initiating therapy, the drug should be discontinued. Patients should be told to contact their doctors immediately when they are aware of a potential thromboembolic symptom (e.g. painful swelling of a leg, sudden pain in the chest, dyspnoea).

  Coronary artery disease (CAD)

  There is no evidence from randomised controlled trials of cardiovascular benefit with continuous combined conjugated estrogens and medroxyprogesterone acetate (MPA). Two large clinical trials (WHI and HERS i.e. Heart and Estrogen/progestin Replacement Study) showed a possible increased risk of cardiovascular morbidity in the first year of use and no overall benefit. For other HRT products there are only limited data from randomised controlled trials examining effects in cardiovascular morbidity or mortality. Therefore, it is uncertain whether these findings also extend to other HRT products.

  Stroke

  One large randomised clinical trial (WHI-trial) found, as a secondary outcome, an increased risk of ischaemic stroke in healthy women during treatment with continuous combined conjugated oestrogens and medroxyprogesterone acetate (MPA). For women who do not use HRT, it is estimated that the number of cases of stroke that will occur over a 5 year period is about 3 per 1000 women aged 50-59 years and 11 per 1000 women aged 60-69 years. It is estimated that for women who use conjugated oestrogens and MPA for 5 years, the number of additional cases will be between 0 and 3 (best estimate = 1) per 1000 users aged 50-59 years and between 1 and 9 (best estimate = 4) per 1000 users aged 60-69 years. It is unknown whether the increased risk also extends to other HRT products.

  Ovarian cancer

  Long-term (at least 5 -10 years) use of oestrogen-only HRT products in hysterectomised women has been associated with an increased risk of ovarian cancer in some epidemiological studies. It is uncertain whether long-term use of combined HRT confers a different risk than oestrogen-only products.

  Other conditions

  Oestrogens may cause fluid retention, and therefore patients with cardiac or renal dysfunction should be carefully observed. Patients with terminal renal insufficiency should be closely observed, since the level of circulating active ingredient in Vagifem^® may be increased.

  Systemic oestrogens have been reported to increase thyroid binding globulin (TBG), leading to increased circulating total thyroid hormone as measured by protein-bound iodine (PBI), T4 levels (by column or by radio-immunoassay) or T3 levels (by radio-immunoassay). T3 resin uptake is decreased, reflecting the elevated TBG. Free T4 and free T3 concentrations are unaltered. Other binding proteins may be elevated in serum, i.e. corticoid binding globulin (CBG), sex-hormone-binding globulin (SHBG), leading to increased circulating corticosteroids and sex steroids respectively. Free or biologically active hormone concentrations are unchanged. Other plasma proteins may be increased (angiotensinogen/renin substrate, alpha-1-antitrypsin, ceruloplasmin). The systemic exposure of estradiol with intermittent administration of low dose estradiol in Vagifem^® may result in less pronounced effects on plasma binding proteins than with oral hormones

  Women with pre-existing hypertriglyceridaemia should be followed closely during oestrogen replacement or hormone replacement therapy, since rare cases of large increases in plasma triglycerides leading to pancreatitis have been reported with oestrogen therapy in this condition.

  There is no conclusive evidence for improvement of cognitive function. There is some evidence from the WHI trial of increased risk of probable dementia in women who start using continuous combined CEE and MPA after the age of 65. It is unknown whether the findings apply to younger post-menopausal women or other HRT products.

• Interactions
  

  None reported.

• Adverse Drug Reactions
  

  More than 640 patients have been treated with Vagifem^® in clinical trials, including over 200 patients treated for between 28 and 64 weeks. Well known oestrogen-related adverse effects which occurred with a higher frequency in the treated group as compared with the placebo group are presented as “Common (>1/100, <1/10)"

  The spontaneous reporting rate on Vagifem^® corresponds to approximately 1 case per 10,000 patient years. Adverse events for which an increased frequency has not been observed in clinical trials, but which have been spontaneously reported and which on an overall judgement are considered possibly related to Vagifem^® treatment are therefore presented as “Very rare (<1/10,000)"

  Post marketing experience is subject to under-reporting especially with regard to trivial and well-known adverse drug reactions. The presented frequencies should be interpreted in that light.

  The most commonly reported adverse drug reactions are: vaginal discharge and vaginal discomfort. Oestrogen-related adverse events such as breast pain, peripheral oedema and postmenopausal bleedings are most likely to present at the beginning of Vagifem^® treatment.

  System organ class	Common >1/100; <1/10	Uncommon >1/1000; <1/100	Rare >1/10,000; <1/1000	Very rare <1/10,000 incl. isolated reports
  Neoplasms benign and malignant (incl. cysts and polyps)				Breast cancer Endometrial cancer
  Immune system disorders				Hypersensitivity, NOS
  Psychiatric disorders				Insomnia Depression
  Nervous system disorders	Headache			Migraine aggravated
  Vascular disorders				Deep venous thrombosis
  Gastrointestinal disorders	Nausea Abdominal pain, abdominal distension or abdominal discomfort Dyspepsia Vomiting Flatulence			Diarrhoea
  Skin and subcutaneous tissue disorders				Urticaria Rash erythematous Rash NOS Rash pruritic General pruritus
  Reproductive system and breast disorders	Genital candidiasis or vaginitis Vaginal haemorrhage, vaginal discharge or vaginal discomfort Breast oedema, breast enlargement, breast pain or breast tenderness			Hyperplasia endometrial Vaginal irritation, vaginal pain, vaginismus, vaginal ulceration
  General disorders and administration site conditions	Oedema peripheral			Fluid retention Drug ineffective
  Investigations				Weight increased Blood oestrogen increased

  Breast cancer

  According to evidence from a large number of epidemiological studies and one randomised placebo-controlled trial, the Women's Health Initiative (WHI), the overall risk of breast cancer increases with increasing duration of HRT use in current or recent HRT users.

  For oestrogen-only HRT, estimates of relative risk (RR) from a reanalysis of original data from 51 epidemiological studies (in which>80% of HRT use was oestrogen-only HRT) and from the epidemiological Million Women Study (MWS) are similar at 1.35 (95%CI 1.21 – 1.49) and 1.30 (95%CI 1.21 – 1.40), respectively.

  For oestrogen plus progestagen combined HRT, several epidemiological studies have reported an overall higher risk for breast cancer than with oestrogens alone.

  The MWS reported that, compared to never users, the use of various types of oestrogen-progestagen combined HRT was associated with a higher risk of breast cancer (RR = 2.00, 95%CI: 1.88 – 2.12) than use of oestrogens alone (RR = 1.30, 95%CI: 1.21 – 1.40) or use of tibolone (RR=1.45; 95%CI 1.25-1.68).

  The WHI trial reported a risk estimate of 1.24 (95%CI 1.01 – 1.54) after 5.6 years of use of oestrogen-progestagen combined HRT (CEE + MPA) in all users compared with placebo.

  The absolute risks calculated from the MWS and the WHI trial are presented below:

  The MWS has estimated, from the known average incidence of breast cancer in developed countries, that:

  • For women not using HRT, about 32 in every 1000 are expected to have breast cancer diagnosed between the ages of 50 and 64 years.

  • For 1000 current or recent users of HRT, the number of additional cases during the corresponding period will be

  o For users of oestrogen-only replacement therapy

  • between 0 and 3 (best estimate = 1.5) for 5 years' use • between 3 and 7 (best estimate = 5) for 10 years' use.

  o For users of oestrogen plus progestagen combined HRT,

  • between 5 and 7 (best estimate = 6) for 5 years' use • between 18 and 20 (best estimate = 19) for 10 years' use.

  The WHI trial estimated that after 5.6 years of follow-up of women between the ages of 50 and 79 years, an additional 8 cases of invasive breast cancer would be due to oestrogen-progestagen combined HRT (CEE + MPA) per 10,000 women years.

  According to calculations from the trial data, it is estimated that:

  • For 1000 women in the placebo group,

  o about 16 cases of invasive breast cancer would be diagnosed in 5 years.

  • For 1000 women who used oestrogen + progestagen combined HRT (CEE + MPA), the number of additional cases would be

  o between 0 and 9 (best estimate = 4) for 5 years' use.

  The number of additional cases of breast cancer in women who use HRT is broadly similar for women who start HRT irrespective of age at start of use (between the ages of 45-65).

  The following adverse reactions have been reported in association with other oestrogen treatment:

  - Myocardial infarction, stroke

  - Gallbladder disease

  - Skin and subcutaneous disorders: chloasma, erythema multiforme, erythema nodosum, vascular purpura, pruritus

  - Risk of development of endometrial cancer, endometrial hyperplasia or increase in size of uterine fibroids*

  - Probable dementia.

  * In non-hysterectomised women.